Written by Jeremiah Velasquez, FNP-BC, AGACNP-BC | Steel City HRT & Weight Loss | NPI: 1841894003

Direct Answer: The most common TRT fears — that it causes heart attacks, feeds prostate cancer, demands estrogen suppression, requires aggressive blood management, and works as a standalone fat-loss solution — have all been directly contradicted by high-level clinical evidence published between 2023 and 2026. The landmark TRAVERSE trial established cardiovascular non-inferiority for testosterone therapy, the FDA removed generalized MI and stroke warnings in February 2025, and the Saturation Model has long since replaced the "testosterone feeds cancer" dogma. Men still making decisions based on these outdated beliefs are either being denied care they need or being over-medicated by clinics optimizing for the wrong numbers.

There are two camps giving Maine men bad information about testosterone therapy, and both of them are costing people years of their health.

The first camp is the old-guard physician who read a 2014 FDA black box warning, never followed the evidence past that point, and reflexively says no to any conversation about TRT. The second camp is the social media optimization crowd telling men to chase testosterone levels of 1,200 ng/dL, crush their estrogen, and layer on ancillary medications they probably don't need.

Most men in Falmouth — and across Maine — are trying to navigate this rationally, and they're getting pulled in both directions at once. They've heard that testosterone therapy is dangerous. They've also heard that their provider is behind the times. Neither camp is giving them the full picture.

The science has caught up. It tells a more nuanced story than either side wants to admit. Here is what men asking questions about low testosterone in Maine actually need to know in 2026 — and what the clinical evidence says.

Why Are So Many Men Still Getting Bad Information About TRT?

You know something is off. You've done the research. You've read conflicting things. That's not a personal failure — that's what happens when a field spends thirty years generating fear-based policy and then tries to walk it back quietly.

Testosterone deficiency — clinically called hypogonadism, defined as the presence of signs and symptoms accompanied by at least two early-morning total testosterone measurements below 300 ng/dL, per American Urological Association guidelines — affects more men than are currently being diagnosed or treated. Those symptoms don't always announce themselves clearly. In Maine, fatigue from low testosterone and fatigue from long winters and shortened daylight can look identical from the outside. Reduced libido, poor sleep, loss of mental edge, and low drive get filed under stress, aging, or seasonal shift. They stay there for years.

The system made that easier. Fifteen minutes in a primary care visit isn't enough time to explore a nuanced hormonal picture. Reference ranges weren't designed around optimization — they were built around population averages. And the fear-based warnings that entered clinical consciousness in 2014 stuck long after the data beneath them began to fall apart.

One. These myths were built on flawed or limited data. Two. They spread through clinical training before the corrections could catch up. Three. And they were reinforced by a healthcare system that had neither the time nor the incentive to revisit them.

Key takeaway: Most of the fear surrounding TRT originated from observational studies and a 2014 FDA action — not from controlled clinical trial data, much of which has since reversed the original conclusions.

What Does the 2026 Evidence Actually Show About Testosterone Therapy?

Here's what most people don't know: the most damning case against TRT's cardiovascular safety was made before a single adequately powered randomized controlled trial had tested it. That changed with TRAVERSE.

The TRAVERSE trial enrolled 5,246 men aged 45 to 80 with pre-existing cardiovascular disease or high cardiovascular risk — the highest-stakes population a trial could select. The primary endpoint was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. The result: 7.0% in the testosterone group versus 7.3% in the placebo group, yielding a hazard ratio of 0.96. That established non-inferiority. According to a 2025 PubMed review of the TRAVERSE study, TRT was not a primary driver of major adverse cardiovascular events in this population. The FDA responded by removing generalized MI and stroke warnings from approved testosterone products on February 28, 2025 — replacing them with a targeted requirement for blood pressure monitoring.

The prostate cancer fear has a similar origin. The foundational study — published in 1941 by Huggins and Hodges — concluded that exogenous testosterone accelerated prostate cancer. That conclusion was based on the clinical result of one patient. Contemporary urology now operates on the Saturation Model, which holds that prostate androgen receptors reach full saturation at testosterone levels between 120 and 240 ng/dL. Beyond that threshold, additional testosterone does not stimulate further prostate growth or malignant transformation. TRAVERSE found no increase in prostate cancer incidence or progression in the testosterone arm compared to placebo.

The estrogen picture is equally distorted. The belief that estradiol is a feminizing liability requiring suppression is the most aggressively marketed myth in the men's health optimization space. According to a 2026 clinical review, only 3% of men on TRT actually require aromatase inhibitor therapy. Estradiol in men is not the enemy — it is essential for bone mineral density, fat mass regulation, and libido. Over-suppression leads to decreased spinal bone density, altered lipid profiles, and joint pain. The evidence-supported target range is 20 to 40 pg/mL, not as low as possible.

Key takeaway: TRAVERSE established cardiovascular non-inferiority for TRT, the FDA removed generalized heart attack and stroke warnings in February 2025, the Saturation Model has replaced the prostate cancer dogma, and routine estrogen suppression is not supported by current evidence — yet most men are still making decisions based on the pre-2023 clinical narrative.

What Does Evidence-Based TRT Actually Look Like in Practice?

Knowing the myths are wrong is one thing. Knowing what evidence-based testosterone replacement therapy actually looks like — and how to tell if you're getting it — is another.

As a board-certified nurse practitioner, Jeremiah Velasquez, FNP-BC, AGACNP-BC, builds every protocol from the 2026 evidence base. Here is what that framework looks like:

One. Target levels in the mid-normal physiological range — 500 to 700 ng/dL. The Endocrine Society and AUA both recommend this window as providing the majority of symptomatic and metabolic benefit with the lowest cardiac and hematological risk profile.

Two. Monitor estradiol in context. A target of 20 to 40 pg/mL supports bone and metabolic health. Aromatase inhibitors are used only when estradiol rises above clinical threshold and the patient is symptomatic — not as a standard protocol add-on.

Three. Manage hematocrit through dose adjustment, not reflexive phlebotomy. Current evidence suggests that frequent phlebotomy can deplete iron stores and lower tissue oxygen levels — paradoxically increasing thrombotic risk. The appropriate threshold for intervention is a hematocrit above 54% with symptoms of hyperviscosity, not any elevation above 50%.

Four. Counsel on HPTA suppression early and clearly. Every form of exogenous testosterone provides negative feedback to the hypothalamus and pituitary, suppressing the body's natural production and impairing spermatogenesis. Pellets, gels, nasal sprays — none of them are exempt. Men wondering whether testosterone replacement is safe for their long-term health in Portland, Maine deserve a provider who explains this upfront, not months after treatment starts.

Five. Set realistic body composition expectations. Meta-analyses of over 30 randomized controlled trials show that TRT combined with lifestyle therapy increases lean mass by approximately 3.4 kg and reduces fat mass by approximately 2.9 kg over one year in hypogonadal men. It improves insulin sensitivity and metabolic function. It is not a fat-loss shortcut — and treating it as one leads to frustration and neglected lifestyle fundamentals.

You either keep navigating conflicting information without clinical support, or you get a real evaluation from a provider working from current guidelines. Those are the options.

Key takeaway: Evidence-based TRT in 2026 targets mid-normal physiological testosterone levels, uses aromatase inhibitors only when clinically indicated, manages hematocrit through dose adjustment rather than routine phlebotomy, counsels clearly on HPTA suppression, and sets realistic expectations for body composition change.

Why Do Maine Men Choose Steel City HRT & Weight Loss?

I have been on both sides of this conversation — as someone who has lived with low testosterone and as a board-certified nurse practitioner who treats it daily. That dual perspective matters here, because the clinical mistakes men run into on TRT are rarely about the hormone itself. They are about protocols built on outdated assumptions, clinics prescribing ancillary medications that serve a business model rather than the patient, and a fractured healthcare system that still has not caught up to the 2026 evidence base.

Steel City HRT & Weight Loss is LegitScript-certified — one of a small number of telehealth clinics to hold that credential — and is fully licensed to serve patients in Maine. There is no clinic visit required. Starting with a complete lab panel, followed by a clinical consultation with a board-certified NP, ending with a protocol built around your actual numbers and your actual goals — that is the process. All monitoring happens through a HIPAA-secure app. All medications are sourced exclusively through 503a-licensed compounding pharmacies. We do not use research-use-only compounds.

Programs available to Maine patients include testosterone replacement therapy, GLP-1 metabolic optimization, peptide therapy, and low-dose naltrexone — all under NP-directed, evidence-based care.

Ready to Get Started? Maine Men Can See a Provider This Week.

If you have been holding off because you were not sure whether TRT was safe, the 2026 evidence has answered that question. The barriers now are access and protocol quality — not the therapy itself.

Men in Falmouth and Portland can complete the entire process from home. No waiting room. No outdated reference range used as a reason to dismiss symptoms that are real. Direct access to a board-certified provider who is working from current clinical guidelines, not 2014 warnings.

You can keep researching and getting pulled in two directions at once, or you can get a real evaluation from a licensed Maine provider who will look at the full clinical picture.

Labs, consult, optimization — that easy.

It all starts at steelcity-trt.com.

Frequently Asked Questions: TRT in Maine

Q: What is the biggest myth about testosterone replacement therapy? A: The biggest myth is that TRT significantly increases the risk of heart attack or stroke. The TRAVERSE trial — a randomized controlled study of 5,246 men — established cardiovascular non-inferiority for testosterone therapy, and the FDA removed generalized MI and stroke warnings from testosterone products in February 2025, replacing them with a targeted requirement for blood pressure monitoring.

Q: Does testosterone therapy cause prostate cancer? A: Current evidence says no. Prostate androgen receptors reach full saturation at testosterone levels between 120 and 240 ng/dL. Additional testosterone above that threshold does not stimulate further prostate growth or malignant transformation. The TRAVERSE trial found no increase in prostate cancer incidence or progression in men receiving testosterone therapy compared to placebo.

Q: Do men on TRT always need an aromatase inhibitor to control estrogen? A: No. A 2026 clinical review found that only 3% of men on TRT require aromatase inhibitor therapy. Estradiol is a critical male hormone — essential for bone density, fat mass regulation, and libido. Routine estrogen suppression is associated with osteoporosis, joint pain, and sexual dysfunction. The evidence-supported estradiol target on TRT is 20 to 40 pg/mL.

Q: Can I get testosterone therapy in Maine without visiting a clinic? A: Yes. Steel City HRT & Weight Loss is fully licensed in Maine and operates as a telehealth clinic with no in-person visit required. The process includes an initial lab panel, a clinical consultation with a board-certified nurse practitioner, and ongoing monitoring through a HIPAA-secure app — all completed remotely from anywhere in Maine.

Q: Will TRT help me lose weight? A: TRT is not a primary fat-loss treatment. Meta-analyses of over 30 randomized controlled trials show TRT combined with lifestyle therapy increases lean mass by approximately 3.4 kg and reduces fat mass by approximately 2.9 kg over one year in hypogonadal men. It improves insulin sensitivity and metabolic function, but caloric restriction and resistance training are still required for significant body composition change.

Q: Is Steel City HRT & Weight Loss available to patients in Maine? A: Yes. Steel City HRT & Weight Loss is LegitScript-certified and fully licensed to provide telehealth care to Maine patients. Services include testosterone replacement therapy, GLP-1 metabolic optimization, peptide therapy, and low-dose naltrexone. No clinic visit is required, and all medications are sourced through 503a-licensed compounding pharmacies.

This content is for informational purposes only and does not constitute medical advice. Consult a licensed provider before beginning any hormone or weight loss therapy. Jeremiah Velasquez, FNP-BC, AGACNP-BC, is a licensed nurse practitioner. Steel City HRT & Weight Loss is a LegitScript-certified telehealth clinic.